Prenetics Global (NASDAQ:PRE – Get Free Report) and Arcellx (NASDAQ:ACLX – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.
Institutional & Insider Ownership
25.0% of Prenetics Global shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 7.8% of Prenetics Global shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Prenetics Global and Arcellx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prenetics Global | -60.70% | -30.12% | -23.87% |
| Arcellx | -607.01% | -51.13% | -33.09% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prenetics Global | $30.62 million | 6.71 | -$46.30 million | ($2.46) | -4.96 |
| Arcellx | $107.94 million | 48.20 | -$107.35 million | ($3.93) | -22.90 |
Prenetics Global has higher earnings, but lower revenue than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Prenetics Global, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Prenetics Global has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for Prenetics Global and Arcellx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prenetics Global | 1 | 0 | 1 | 0 | 2.00 |
| Arcellx | 1 | 1 | 7 | 1 | 2.80 |
Prenetics Global presently has a consensus target price of $32.00, indicating a potential upside of 162.30%. Arcellx has a consensus target price of $115.50, indicating a potential upside of 28.36%. Given Prenetics Global’s higher probable upside, equities analysts plainly believe Prenetics Global is more favorable than Arcellx.
Summary
Prenetics Global beats Arcellx on 8 of the 15 factors compared between the two stocks.
About Prenetics Global
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
About Arcellx
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company’s preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
